• 1. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 2. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 5. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584

Recent Advances in the Study of 3-(4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)methylbenzoic Acid (CAS: 175203-24-4)

3-(4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)methylbenzoic Acid (CAS: 175203-24-4) is a chemically synthesized compound that has garnered significant attention in the field of chemical biology and medicinal chemistry. Recent studies have explored its potential as a versatile scaffold for drug development, particularly in targeting inflammatory pathways and enzyme modulation. This research brief aims to synthesize the latest findings on this compound, highlighting its structural characteristics, biological activities, and therapeutic applications.

Structural analysis reveals that the compound features a pyrazole ring substituted with bromo and methyl groups, coupled with a benzoic acid moiety via a methylene linker. This unique architecture enables interactions with various biological targets, including kinases and G-protein-coupled receptors (GPCRs). A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy as a selective inhibitor of COX-2, showcasing its potential as a non-steroidal anti-inflammatory drug (NSAID) candidate with reduced gastrointestinal side effects compared to traditional NSAIDs.

In addition to its anti-inflammatory properties, recent in vitro studies have investigated the compound's role in cancer therapy. Research conducted by the University of Cambridge in 2024 identified its ability to induce apoptosis in certain cancer cell lines by modulating the PI3K/AKT/mTOR pathway. These findings were further supported by molecular docking simulations, which highlighted strong binding affinities to key oncogenic proteins. However, challenges such as bioavailability and metabolic stability remain to be addressed in preclinical models.

The compound's synthetic accessibility has also been a focus of recent publications. A 2024 Organic Letters paper detailed an optimized three-step synthesis route, achieving a 78% overall yield with improved purity profiles. This advancement is critical for scaling up production for future pharmacological evaluations. Furthermore, computational studies have predicted favorable ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties, though experimental validation is still pending.

Despite these promising developments, gaps in the literature persist. For instance, the compound's effects on non-mammalian systems and its potential as an antimicrobial agent remain underexplored. Collaborative efforts between academia and industry are expected to drive further research, particularly in structural derivatization to enhance target specificity. As of mid-2024, no clinical trials involving this compound have been registered, underscoring the need for robust preclinical data to justify translational studies.

In conclusion, 3-(4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)methylbenzoic Acid represents a multifaceted tool for drug discovery, with applications spanning inflammation, oncology, and beyond. Its mechanistic versatility and synthetic tractability position it as a compelling subject for future investigations. Researchers are encouraged to explore its off-target effects and formulation strategies to unlock its full therapeutic potential.

• 51108-53-3(1-Benzyl-4-bromo-3,5-dimethyl-1H-pyrazole)
• 512826-72-1(3-(4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)methyl-4-methoxybenzaldehyde)
• 402736-52-1(3-(4-Bromo-1H-pyrazol-1-yl)methylbenzoic Acid)
• 1262415-66-6(ethyl 1-benzyl-4-bromo-5-methyl-pyrazole-3-carboxylate)
• 387344-96-9(4-[(4-Bromo-1H-pyrazol-1-yl)methyl]benzoic acid)
• 956392-62-4(2-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)methylquinoline-4-carboxylic acid)
• 376359-05-6(3-(3,5-Dimethyl-1H-pyrazol-1-yl)methylbenzoic Acid)
• 175203-23-3(Methyl 3-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)-methylbenzoate)
• 376372-41-7(4-(4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)methylbenzoic acid)
• 312531-87-6(4-(3,5-Dimethyl-1H-pyrazol-1-yl)methylbenzoic Acid)